UniQure stock falls after news of new CFO, acquisition, and new trial data
Shares of UniQure N.V., a Netherlands-based biotech with U.S. headquarters in Lexington, fell on Tuesday after three very different announcements involving a new top executive, an acquisition and new trial data.
UniQure (Nasdaq: QURE) share prices were hovering around $30 as of 2:45 p.m., a decrease of more than 8%, giving the company a market cap of $1.4 billion.
The company earlier in the day announced positive topline data from a Phase 3 study of its hemophilia B drug, etranacogene dezaparvovec,…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Rowan Walrath Source Type: news
More News: American Health | Biotechnology | Haemophilia | Health Management | Hemophilia | Mergers and Aquisitions | Netherlands Health | Study